Gastrodin (Gastrodia elata).

Gastrodin has been reported to raise GABA tone by slowing GABA transaminase, the enzyme that degrades GABA. L-theanine works on the other side of the balance, damping glutamate signalling and raising alpha-band cortical activity, so the two act on excitation and inhibition through separate handles.

Magnesium sits in the NMDA receptor channel as a voltage-dependent block and is a cofactor for glutamate decarboxylase, the enzyme that builds GABA. Alongside gastrodin's reported slowing of GABA breakdown, both act on the same inhibitory balance from different points.

Gastrodin and its aglycone gastrodigenin slow GABA transaminase, the enzyme that degrades GABA, so more of the transmitter stays available. Supplying GABA gives that conserving action something to work on.

Magnesium sits in the NMDA receptor pore and damps glutamate-driven excitation, while gastrodin works on the inhibitory GABA side. The two approach the excitatory and inhibitory balance from opposite ends.

Glutamate decarboxylase needs pyridoxal 5-phosphate to make GABA at all. Pyridoxine supports the synthesis step while gastrodin slows the breakdown step.

Rosmarinic acid from lemon balm also inhibits GABA transaminase, which is where gastrodin acts. Combining them presses on one enzyme from two chemistries, so dosing should be considered together.

Valerenic acid modulates the GABA-A receptor and valerian constituents also affect GABA uptake. That receptor-level action sits beside gastrodin's effect on transmitter turnover.

Passionflower flavonoids modulate the GABA-A channel while gastrodin keeps more GABA around to activate it. Receptor sensitivity and transmitter availability are different levers.

Apigenin binds the benzodiazepine site of GABA-A and changes how the channel responds to GABA. Gastrodin raises the GABA that receptor then sees.

Honokiol increases GABA-evoked chloride current, an effect that depends on the transmitter being present. Gastrodin's slowing of GABA breakdown supplies that.

Gastrodin is a beta-D-glucoside, and glucoside bonds of this class are cleaved by bacterial beta-glucosidases in the gut to release the aglycone. The composition of that bacterial population therefore influences how much aglycone is generated from a given dose. What is established is the chemistry of the conversion, not that a particular probiotic strain changes it in people.

Fermentable fructans expand populations of saccharolytic gut bacteria, the same group that carries beta-glucosidase activity capable of cleaving plant glucosides. The proposed link runs through the microbial enzyme pool. It is a plausible mechanism that has not been measured for this compound, so it is marked early.

Gastrodia preparations appear alongside melatonin in evening formulas, one acting on circadian signalling through MT1 and MT2 receptors and the other studied for GABAergic activity in preclinical work. The routes are separate. No combination study exists, so this is formulation convention.

Glycine is itself an inhibitory neurotransmitter at its own strychnine-sensitive receptor and as a co-agonist at NMDA receptors, and it is used in evening formulas for that reason. Preclinical work on gastrodin has centred on GABAergic signalling. Both point in a calming direction, which is worth flagging for anyone already using a sedating medication.

Chamomile carries apigenin, a flavone with benzodiazepine-site binding in preclinical assays, and gastrodin has been studied at GABAergic targets in animals. The pairing is common in evening teas and capsules. Additive calming is the direction to watch when other sedating agents are in use.

Tryptophan is hydroxylated and decarboxylated to serotonin, which is converted onward to melatonin in the pineal gland. Gastrodin's preclinical work sits on a different neurotransmitter system. The two are combined in evening products on rationale rather than on a combination trial.

Ashwagandha is used as an adaptogen with human trials reading out perceived stress and cortisol markers, while Gastrodia rhizome sits in traditional Chinese use for calm and head comfort. Products combine them across those two traditions. No study has measured the combination.

Bacopa has human trials measuring memory task performance over weeks, and Gastrodia preparations appear in the same category of formulas. The proposed routes differ, with bacosides studied for cholinergic and antioxidant activity. Read the pairing as formulation convention rather than a measured interaction.

Ginkgo and Gastrodia appear together in traditional and modern head-comfort formulas. Ginkgo carries a documented antiplatelet signal, so the combination deserves a caution for anyone on anticoagulant or antiplatelet medication. That caution comes from ginkgo, not from gastrodin.

Animal work on gastrodin repeatedly reads out tissue glutathione and malondialdehyde as oxidative markers, with gastrodin associated with higher reduced glutathione in those models. Those are markers in animals, not outcomes in people. The pairing is mechanistic and belongs in that register.

N-acetylcysteine supplies cysteine, the rate-limiting amino acid for glutathione synthesis, while gastrodin's preclinical signal includes upregulation of endogenous antioxidant enzymes through Nrf2 signalling. One raises substrate, the other is described as raising enzyme expression in animals. The convergence is on the same defence system, measured only preclinically for gastrodin.

Rhodiola is used for perceived fatigue with human trials on mental work capacity, and Gastrodia is used in the calm and head-comfort category. Products combine the two for coverage across daytime and evening use. No combination study exists.

Taurine acts at glycine and GABA-A receptors as a weak agonist and is used as an osmolyte and neuromodulator in calming formulas. Gastrodin's preclinical work overlaps at GABAergic signalling. The overlap is at the receptor level and only measured in preclinical systems.